Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stifel Maintains Hold on Neumora Therapeutics, Raises Price Target to $3

Author: Benzinga Newsdesk | November 17, 2025 08:52am
Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises the price target from $2 to $3.

Posted In: NMRA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist